Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Ma...( OGX-011 may reverse docetaxel resist...)

survival. In July 2008, OncoGenex Technologies reached an agreement

with the U.S. Food and Drug Administration (FDA) on the design of a

Phase 3 registration trial of OGX-011 via the Special Protocol

Assessment (SPA) process;

- OGX-427 is designed to reduce production of Hsp27, a protein that is

over-produced in response to many cancer treatments including hormone

ablation therapy, chemotherapy and radiation therapy. Hsp27

production has been shown to inhibit cell death in tumor cells

through a variety of mechanisms. OGX-427 is in a Phase 1 clinical

trial for the treatment of solid tumors including prostate, non-small

cell lung, breast, ovarian, and bladder cancers. The Company

anticipates that the safety profile for OGX-427 as a single agent

will be completed in the second half of 2008, and for OGX-427 in

combination with chemotherapy in the first half of 2009. Phase 2

clinical development will begin in 2009. Like OGX-011, this product

candidate has potential as a treatment in a broad number of cancers;

- SN2310 is a novel prodrug of SN-38, which is a potent anti-cancer

drug belonging to the class of topoisomerase I inhibitors. SN2310 is

designed to enhance the delivery and exposure of SN-38 to the tumor

by providing greater prodrug conversion and a longer half-life than

achieved with irinotecan. It is currently in a Phase 1 trial and

progress is being made to determine its safety and pharmacokinetic

profile, in addition to the maximum tolerated dose;

- CSP-9222 is a caspase activator presently in pre-clinical

development. Caspase activators consist of small molecules that have

been identified in preclinical research as activators of programmed